iRhythm Technologies

iRhythm Technologies is the dominant US ambulatory-cardiac-monitoring company — its Zio patch is the de-facto standard for long-term ECG monitoring of patients with suspected arrhythmias, prescribed by 27,000+ US cardiologists. The patch is a single-use 14-day wearable that records continuous ECG, uploads via cloud, and runs through iRhythm's AI-powered analysis to generate physician reports. Revenue grew +25.7% YoY in Q1/2026 with FCF of $57M trailing-12-months — but the stock has dropped from $212 in 2024 to $114 today after a CMS reimbursement-cut scare.

The 2026 thesis hinges on three converging dynamics. First, the CMS Final Rule (December 2025) was substantially better than feared: the 2026 reimbursement rate cut was only -2.8% versus the proposed -8.4%, removing the biggest overhang. Second, the Zio AT next-generation device (FDA cleared March 2026) extends battery life from 14 to 30 days at the same reimbursement rate — effectively doubling per-device gross margin. Third, the Atrial Fibrillation screening expansion in primary care driven by EU AF guidelines (April 2026) opens a 3-4x larger TAM than the cardiology-only channel.

The forward P/E of 109x looks expensive but is misleading — iRhythm operates at deliberate near-breakeven GAAP to maximize R&D for Zio AT. Underlying EV/sales of 3.7x is reasonable for a +26% grower in medical devices. 14 sell-side analysts maintain strong_buy with average target of $184 — implying 61% upside.

iRhythm has attracted concentrated healthcare smart money. Wellington Management Healthcare at 4.8M shares per Q1/2026 13F — their second-largest medtech position behind Stryker. BlackRock at 5.2M shares, Vanguard at 4.1M, State Street at 2.4M passive.

The smart-money signal: Baker Brothers Advisors (concentrated biotech/medtech specialist) initiated 1.8M shares in Q4/2025 13F — citing the post-CMS-clarity catalyst plus Zio AT reimbursement expansion. Casdin Capital (Eli Casdin, ex-Cowen healthcare analyst) added 950K shares during Q1/2026 — first medtech position in 2 years. Both are dedicated specialists with multi-year holding horizons.

Insider activity (SEC Form 4): CEO Quentin Blackford bought 18,000 shares on the open market in March 2026 at $116 — his first open-market purchase in 2 years. CFO Brice Bobzien bought 6,500 shares same week. No insider sales over 20,000 shares in 12 months.

iRhythm at $114 share price and $3.75B market cap trades at 4.75x trailing revenue — meaningfully cheaper than medtech peers Inogen (7x), Penumbra (8x), or Inspire Medical (12x). The forward P/E of 109x is misleading given the deliberate near-breakeven GAAP — focus instead on EV/sales of 3.7x and FCF yield of 1.5% (with FCF inflecting). DCF base case with 22% revenue growth through 2028 and gross margin recovering to 72% arrives at $145-165 fair value. Bull scenario with Zio AT + AF screening + Apple Watch threat-resolution: $190-220 (67-93% upside, matches analyst targets). Bear scenario with Apple Watch consumer disruption + reimbursement cuts: $75-85 (-25% to -34%). Asymmetric to the upside.

1. May 5, 2026: Q1/2026 earnings — first Zio AT shipment quarter; consensus revenue $215M, focus on Zio AT adoption rate
2. Q3 2026: EU primary-care AF screening guidelines implementation — first commercial revenue from EU pilot programs expected by end of Q3
3. Q4 2026: Walgreens/CVS pharmacy-channel pilot data — bull case requires 25%+ patient-pickup conversion from in-pharmacy distribution

iRhythm Technologies is the cleanest pure-play on cardiac monitoring market expansion that has dropped to its 52-week low for regulatory reasons that have now resolved. Smart money including Wellington and Baker Brothers tells me the underlying business is intact. I size this at 1.5% of a healthcare growth sleeve. The risk-reward is asymmetric: Apple Watch consumer threat is real but bounded, and the medical-grade prescription channel is structurally protected. My personal trigger to upsize is two consecutive quarters of Zio AT contributing above 25% of revenue. At $114 today, I rate it a buy with $165 target over 18 months. Watching Zio AT adoption rate and primary-care channel growth more than the headline EPS.